Biotech giants are racing to dominate a weight-loss sector projected to hit $100 billion in yearly revenue over the next decade. Leading firms like Eli Lilly and Novo Nordisk are currently pivoting toward oral medications and high-potency injections to maintain their market lead. This competition involves a diverse array of delivery methods, from daily pills to once-monthly shots.
The 2030 Pivot Toward a 50% Market Share for Oral Pills
The delivery mechanism for obesity drugs is undergoing a fundamental shift. Novo Nordisk CEO Mike Doustdar stated in September that oral weight-loss pills could command as much as half of the global market by 2030. This transition aims to replace the inconvenience of injections with easier-to-administer tablets, a move that could democratize access to these treatments.
Eli Lilly is already making significant inroads in this space. According to the report, Eli Lilly has captured more than 30% of new patients in the United States for oral obesity treatments, challenging the early advantage held by Novo Nordisk's Wegovy pill. Furthermore, Eli Lilly's oral drug Foundayo recently received approval from Britain's medicines regulator in August and a positive recommendation from the European Medicines Agency committee in October.
Retatrutide's 28% Weight Loss and the Battle for Potency
While convenience is key, the industry is also engaged in an arms race for efficacy. Eli Lilly's next-generation drug, retatrutide, demonstrated a weight loss of more than 28% over 18 months in a May trial. This positions retatrutide as a potentially devastating competitor to existing therapies , with a possible launch expected as early as next year.
Lilly is also testing combination therapies to push these boundaries. The experimental drug EloraTZP, which combines tirzepatide and eloralintide, outperformed Zepbound in a mid-stage trial. Patients using the highest dose of EloraTZP lost an average of 23.3% of their body weight over 48 weeks, whereas those on Zepbound lost 14.8%, as reported in the source material.
Novo Nordisk's $2 Billion Bet on China's United Laboratories
Novo Nordisk is diversifying its pipeline to defend its territory.. The company signed a licensing agreement worth up to $2 billion with China-based United Laboratories to develop a "triple-G" weight-loss candidate that targets three different hormones. This strategic move suggests that Novo Nordisk beieves the next leap in weight loss will come from multi-hormone targeting rather than single-pathway drugs.
However, Novo Nordisk has faced some setbacks. While its experimental injection amycretin showed a 14.5% weight loss in type 2 diabetes patients over 36 weeks, the drug CagriSema underperformed expectations. CagriSema helped patients lose 22.7% of their weight in one late-stage trial, falling short of the 25% target set by Novo Nordisk.
Pfizer's 2028 Target and Roche's $2.7 Billion Carmot Acquisition
Beyond the two primary leaders, other pharmaceutical giants are spending billions to enter the fray. Roche acquired the US biotech firm Carmot Therapeutics for $2.7 billion in 2023, gaining access to enicepatide. In mid-stage trials, enicepatide helped patients with type 2 diabetes lose an average of 15.5% of their body weight, with late-stage studies planned for the first half of 2027.
Pfizer is pursuing a different strategy by focusing on dosing frequency.. Through its acquisition of Metsera, Pfizer is developing PF-3944, a GLP-1 therapy designed as a once-monthly injection. Pfizer reported in February that this drug led to 12.3% weight loss in non-diabetic patients without a plateau at week 28. Pfizer is currently targeting 2028 for its first regulatory approval in the sector.
The Unverified Long-Term Impact of PF-3944's Monthly Dosing
Despite the optimistic clinical data, several critical gaps remain. While Pfizer noted in June that PF-3944 has a side-effect profile similar to Novo Nordisk's weekly Wegovy, it remains unclear if a monthly dose creates different long-term metabolic stresses compared to weekly administration. Additionally, the source focuses heavily on clinical percentages but provides no data on the projected pricing of these next-generation drugs or how insurance providers will handle the transition from weekly to monthly or oral treatments.
Comments 0